Intraventricular pentosan polysulphate in human prion diseases: An observational study in the UK

European Journal of Neurology

Volumn 15, Issue 5, 2008, Pages 458-464

  Bone, I ^a   Belton, L ^b   Walker, A S ^b   Darbyshire, J ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Creutzfeldt Jakob disease; Intraventricular drug infusion; Pentosan polysulphate

Indexed keywords

ANTIBIOTIC AGENT; FLUPIRTINE; MEMANTINE; MEPACRINE; MINOCYCLINE; PENTOSAN POLYSULFATE; THALIDOMIDE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FEVER; GENE MUTATION; GENOTYPE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; NEUROSURGERY; PATIENT MOBILITY; PNEUMONIA; PRION DISEASE; PRIORITY JOURNAL; SEIZURE; SKIN BRUISING; SURVIVAL TIME; TONIC CLONIC SEIZURE; TREATMENT DURATION;

ADULT; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; INJECTIONS, INTRAVENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; OBSERVATION; PENTOSAN SULFURIC POLYESTER; PRION DISEASES; TREATMENT OUTCOME;

EID: 41849091490     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02108.x     Document Type: Article

References (27)

1. Collinge J. Molecular neurology of prion disease. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 : 906 919.
2. Caughey B, Caughey W, Kocisko D, et al. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics. A common mechanism for anti-TSE compounds. Accounts of Chemical Research 2006 39 : 646 653.
3. Head MW, Farquhar CF, Mabbott NA, Fraser JR. The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention. Expert Opinion on Therapeutic Targets 2001 5 : 569 585.
4. Kimberlin RH, Farquhar CF, Walker CA, Dickinson AG. Suppression of scrapie infection in mice by inorganic and organic polyanions. In : Tateishi J ed. Proceedings of Workshop on Slow Transmissible Diseases. Tokyo : Japanese Ministry of Health and Welfare, 1984 : 119 128.
5. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. Journal of General Virology 1984 65 : 1325 1330.
6. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. Journal of General Virology 1986 67 : 463 473.
7. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulphate and some other polyanions. Antimicrobial Agents and Chemotherapy 1986 30 : 409 413.
8. Janssen-Ortho Inc. Product Monograph: Elmiron (Pentosan Polysulfate Sodium). Janssen-Ortho Inc., Toronto: Canada, January 2006. Available at: http://www.janssen-ortho.com
9. MacGregor IV, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man. Catabolism of iodinated derivatives. Thrombosis and Haemostasis 1984 51 : 321 325.
10. Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. Journal of Virology 2004 78 : 4999 5006.
11. Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999 353 : 117.
12. Dealler S, Rainov N. Pentosan polysulphate as a prophylactic and therapeutic agent against prion disease. IDrugs 2003 6 : 470 478.
13. Dealler S. Post-exposure prophylaxis after accidental prion inoculation. Lancet 1998 351 : 600.
14. Todd N, Morrow J, Doh-ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jacob disease. Journal of Infection 2005 50 : 394 396.
15. Rainov N, Whittle I, Doh-ura K. Treatment options in patients with prion disease. The role of long term cerebroventricular infusion of pentosan polysulphate. In : Kitamoto T ed. Prions (Food and Drug Safety). Tokyo : Springer-Verlag, 2005.
16. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-ura K. Experimental treatment for human transmissible spongiform encephalopathies: is there a role for pentosan polysulphate? Expert Opinion Biological Therapy 2007 7 : 1 14.
17. Parry A, Baker I, Stacey R, Wimalaratna S. Long-term survival in a patient with vCJD treated with intraventricular pentosan polysulphate. Journal of Neurology, Neurosurgery and Psychiatry 2007 78 : 733 734.
18. MRC Clinical Trials Unit. Prion-1 Trial: Quinacrine for human prion disease. A partially randomised patient preference trial to evaluate the activity and safety of quinacrine in human prion disease. Available at: http://www.ctu.mrc.ac.uk/studies/cjd.asp (accessed 28/07/2007).
19. Medical Research Council. Intraventricular pentosan polysulphate in human prion disease - a study of experience in the United Kingdom (issued 1 June 2006). Available at: http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d= MRC003453 (accessed 28/07/2007).
20. Pocchiari M, Puopolo M, Croes AE, et al. Predictors of survival in sporadic Creutzfeldt-Jacob disease and other human transmissible spongiform encephalopathies. Brain 2004 127 : 2348 2359.
21. Stewart L, Rydzewska L, Keogh G, Knight RSG. A systematic review of therapeutic interventions in human prion disease. Neurology (in press).
22. Abbott NJ. Evidence for bulk flow of the brain interstitial fluid: significance for physiology and pathology. Neurochemistry International 2004 45 : 545 552.
23. Fenstermacher J, Ghersi-Egea J, Finnegen W, et al. The rapid flow of cerebrospinal fluid from ventricles to cisterns via the subarachnoid velae in the normal rat. Acta Neurochirurgica Supplement 1997 70 : 285 287.
24. Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jacob disease. Current Topics in Microbiology and Immunology 2004 284 : 133 159.
25. DeArmond SJ, Ironside JW, Bouzamondo-Berstein E, Peretz D, Fraser JR. Neuropathology of prion diseases. In : Prusiner SB, ed. Prion Biology and Diseases, 2nd edn. New York : Cold Spring Harbor, 2004 : 777 856.
26. Yerby MS, Sundsten JW, Larson EB, Wu SA, Sumi SM. A new method of measuring brain atrophy: the effect of aging in its application for diagnosing dementia. Neurology 1985 35 : 1316 1320.
27. Frisoni GB, Scheltens P, Galluzzi S, et al. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry 2003 74 : 1371 1381.